CureVac raises EUR 27.6 Million in Financing Round
2010-05-10 13:37:10 -
CureVac GmbH / CureVac raises EUR 27.6 Million in Financing Round processed and transmitted
by Hugin AS. The issuer is solely responsible for the content of this announcement.
Tübingen (Germany), May 10, 2010. CureVac GmbH, the mRNA vaccine company, today
announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round
with its major shareholder, dievini Hopp BioTech holding
GmbH & Co. KG.
The proceeds will enable further clinical development of RNActive® therapeutic
vaccines against solid tumours. The funds will also help to accelerate
preclinical and clinical development of prophylactic vaccines against infectious
Currently, CureVac's lead compound to treat prostate cancer, CV9103, is in a
Phase IIa trial, with results expected in the second half of 2010. In a separate
Phase I study, the company is developing CV9201, an mRNA vaccine compound to
treat non-small cell lung cancer (NSCLC).
"Since its foundation, CureVac, a spin-off from Tübingen University, has raised
a total of EUR 65 million (US$ 83 million). This significant funding shows
clearly the faith and confidence of our main investor, dievini Hopp" said Ingmar
Hoerr, CEO of CureVac. "The proceeds from this financing round will allow us to
further develop our mRNA immunotherapeutics for the treatment of prostate cancer
and NSCLC. Furthermore, the funds will enable us to speed up the development of
our very promising prophylactic vaccine platform against infectious diseases as
well as to further develop our novel RNA-based adjuvants."
"Based on its unique mRNA-based RNActive® technology and on all the data,
knowledge and patents generated so far, we think that CureVac is in a strong
position to become an important player in future immunotherapy," said Friedrich
von Bohlen, managing partner of dievini Hopp Biotech Holding GmbH & Co. KG.
"With this further funding from our side, CureVac is able to develop its
promising therapeutic and prophylactic vaccine candidates. We are convinced that
immunotherapeutic approaches will become more and more important in future
therapy and prophylaxis of infectious diseases as well as the fight against
cancer," Friedrich von Bohlen added.
CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and
therapeutic application of messenger RNA (mRNA). CureVac's lead programme is
dedicated to the development of active immunotherapies (based on its RNActive®
technology) for the treatment of prostate cancer and non-small cell lung cancer.
Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines
and adjuvants to address infectious diseases.
Currently, there are two candidates in clinical development: CV9103 to treat
prostate cancer, which, in the U.S. and Europe, is the most common cancer and
the second leading cause of cancer death in men, and CV9201, to treat non-small
cell lung cancer (NSCLC). Lung cancer affects more than 1.4 million people
worldwide and is the leading cause of cancer death.
CureVac, a spin-off from the Tübingen University, Germany, was established in
December 2000 and is headquartered in Tübingen with clinical development
facilities in Frankfurt. Since its inception, the Company has raised
approximately EUR 65 million. The principal investor of the company is dievini
Hopp BioTech holding GmbH&Co. KG, the biotech investment firm of the Hopp
RNActive®, RNAdjuvant®, PUREmessenger® are registered trademarks of CureVac
About CureVac's mRNA-derived Technologies
Messenger ribonucleic acid (mRNA) is a genetic template for protein synthesis.
It delivers the information encoded by genes from DNA to ribosomes where the
information is translated into individual proteins. Natural RNA is an unstable
biomolecule that is rapidly digested in the human body. As a result, its
potential role as a therapeutic has been overlooked for decades.
CureVac has proved it is possible to modify mRNA making it suitable for
therapeutic purposes and maintaining its physiological properties. CureVac's
RNActive®-derived customized mRNA molecules are used to encode different
antigens that are expressed by cells residing in the upper layers of the skin.
Hence, the immune system will recognize these antigens on presentation to
dendritic cells and react by forming both antigen-specific T-cells and humoral
Building on its unique expertise from many years of RNA research and molecular
design, the Company has established proprietary technologies. Furthermore,
CureVac has built up a worldwide unique production plant for manufacturing
pharmaceutical grade mRNA according to cGMP (current Good Manufacturing
Practice). The combination of these technologies enables the Company to design
and manufacture mRNA for a broad range of applications.
Marijke Barner, PhD
--- End of Message ---
Paul-Ehrlich-Str. 15 Tübingen Germany